Teva Pharmaceutical Industries (MEX:TEVA N) ROCE %: 9.49% (As of Mar. 2026)


MEX:TEVA N Teva Pharmaceutical Industries Ltd MEX:TEVA N
40 GF Score
Price MXN597.50
GF Value MXN347.38
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Teva Pharmaceutical Industries ROCE %?

Teva Pharmaceutical Industries MEX:TEVA N 40 ROCE % is 9.49% as of Mar. 2026. GuruFocus rates MEX:TEVA N with a GF Score™ of 40/100 and a GF Value™ of MXN347.38 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Teva Pharmaceutical Industries's annualized ROCE % for the quarter that ended in Mar. 2026 was 9.49%.

Teva Pharmaceutical Industries  (MEX:TEVA N) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Teva Pharmaceutical Industries ROCE % Related Terms

Teva Pharmaceutical Industries ROCE % Historical Data

* Premium members only.

The historical data trend for Teva Pharmaceutical Industries's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries ROCE % Chart

Teva Pharmaceutical Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.25 -6.28 1.18 -1.09 7.37

Teva Pharmaceutical Industries Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.45 5.61 11.92 5.30 9.49
MEX:TEVA N
40GF Score
Teva Pharmaceutical Industries Ltd MEX:TEVA N
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Teva Pharmaceutical Industries ROCE % Calculation

Teva Pharmaceutical Industries's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=38514.192/( ( (820171.258 - 266869.537) + (733696.264 - 242284.699) )/ 2 )
=38514.192/( (553301.721+491411.565)/ 2 )
=38514.192/522356.643
=7.37 %

Teva Pharmaceutical Industries's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=46019.452/( ( (733696.264 - 242284.699) + (722029.309 - 244018.497) )/ 2 )
=46019.452/( ( 491411.565 + 478010.812 )/ 2 )
=46019.452/484711.1885
=9.49 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 9.49% mean?
Teva Pharmaceutical Industries (MEX:TEVA N) has a ROCE % of 9.49% as of Mar. 2026.
Is Teva Pharmaceutical Industries' ROCE % too high?
Teva Pharmaceutical Industries' current ROCE % is 9.49%. The Drug Manufacturers industry median ROCE % is 7.03. Teva Pharmaceutical Industries' value of 9.49% is 35% above this industry median. Overall, Teva Pharmaceutical Industries has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' ROCE % compare to ZTS and UTHR?
Teva Pharmaceutical Industries' ROCE % of 9.49% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Teva Pharmaceutical Industries' value of 9.49% is 35% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current ROCE % of 9.49% is 35% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current ROCE % is 9.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (MEX:TEVA N) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN347.38, compared to a current price of MXN597.50 — trading 72% above its estimated fair value. The current ROCE % is 9.49% and 35% above the Drug Manufacturers industry median of 7.03. Teva Pharmaceutical Industries' overall GF Score™ is 40/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Teva Pharmaceutical Industries (MEX:TEVA N), the current ROCE % is 9.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Teva Pharmaceutical Industries (MEX:TEVA N) Overvalued in 2026?

Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued. The current stock price of MXN597.50 is trading 72% above its estimated GF Value™ of MXN347.38. GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.

Key valuation signals for MEX:TEVA N:

  • ROCE %: 9.49%
  • GF Value™: MXN347.38 vs. price of MXN597.50 (72% above fair value)
  • GF Score™: 40/100 with 5 warning signs
  • Industry Position: 35% above the Drug Manufacturers median

No single metric tells the full story. See the MEX:TEVA N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Teva Pharmaceutical Industries Business Description

Address 124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
40GF Score

Get the complete analysis for MEX:TEVA N

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN597.50
Price
MXN347.38
GF Value